LifeVantage Corporation — FY2013 Form 10-K
Reporting period: Fiscal year ended June 30, 2013. The request metadata refers to “2012 Q4,” but this filing is an annual report for FY2013; it also reports fourth-quarter FY2013 results. LifeVantage sells dietary supplements and skin-care products, primarily through independent distributors and preferred customers. Its flagship product is Protandim.
Financial results and liquidity
| Metric | FY2013 | FY2012 |
|---|---|---|
| Net sales | $208.2 million | $126.2 million |
| Gross profit / reported gross margin | $171.5 million / 82.4% | $108.1 million / 85.7% |
| Operating income / margin | $12.1 million / 5.8% | $21.5 million / 17.0% |
| Net income | $7.6 million | $12.5 million |
| Diluted earnings per share | $0.06 | $0.11 |
| Cash from operations | $10.7 million | $19.4 million |
- Sales rose 65%, with increases of $42.9 million in the Americas and $39.1 million in Asia/Pacific. Japan contributed $69.5 million, about one-third of revenue.
- Recall costs were $4.8 million in the income statement; management reported approximately $5.0 million of total net recall expense. The filing also records $3.9 million of inventory write-downs, primarily related to the recall.
- Sales and marketing expense increased to $122.4 million from $68.4 million, largely reflecting distributor commissions on higher sales. General and administrative expense rose to $32.5 million from $16.4 million.
- Cash and cash equivalents were $26.3 million at year-end, working capital was $25.4 million, and total liabilities were $21.5 million. The company reported no outstanding debt and no off-balance-sheet arrangements.
- Investing activities used $5.1 million, primarily for fixed assets. Financing activities used $4.0 million, including $7.1 million of share repurchases, partly offset by proceeds from option and warrant exercises.
Material changes and unusual items
- In December 2012, LifeVantage voluntarily recalled certain Protandim lots over concerns that tablets could contain small metal fragments originating in turmeric extract. The company says the recall reduced sales and slowed new customer and distributor enrollments in the third and fourth quarters. It implemented additional quality-control measures and added manufacturing capacity through a third contract manufacturer.
- Japan transitioned from a “not-for-resale” arrangement to direct selling, requiring distributor and customer re-enrollment. A Japanese regulatory determination concerning ashwagandha also led to a reformulated Protandim product for that market. Management attributed slower Japanese growth partly to these changes and the recall.
- Active independent distributors increased to about 67,000 from 46,000; active preferred customers increased to about 138,000 from 119,000. The company opened in Hong Kong and expanded its product line with Canine Health.
- LifeVantage listed its common stock on the NASDAQ Capital Market during FY2013. It repurchased 2.97 million shares for $7.1 million during the year.
- Net income declined despite strong sales growth: higher operating expenses and recall-related costs outweighed lower other expense. The prior-year comparison included $6.7 million of derivative-liability expense; no derivative liability instruments remained at June 30, 2013.
Outlook, risks and contingencies
- Management expected FY2014 sales to grow, but at a reduced rate. It expected gross margin of approximately 84%–85% for the foreseeable future and sales and marketing costs to rise with sales while remaining relatively stable as a share of revenue.
- Management said available cash and operating cash flow should cover requirements for at least the next 12 months. It noted that additional financing could be considered if needed, with no assurance of favorable availability or terms.
- Management announced an intention to conduct a self-tender offer for up to $40 million of common stock; the offer had not commenced as of the filing. Shareholders were directed to review the eventual offer materials.
- Key risks include dependence on Protandim, product quality and recall exposure (the company says it has no product-recall insurance), third-party manufacturing, Japanese regulatory and market risks, distributor retention and compliance, direct-selling regulation, foreign exchange exposure, and competition. Approximately 37% of FY2013 sales were international.
- A distributor lawsuit filed in Utah sought more than $20 million, alleging breach of agreement and trade-secret misappropriation. LifeVantage denied the allegations and said it would defend the case; the financial-statement note says management considered adverse outcomes remote for lawsuits generally.
- The filing reports that disclosure controls and internal control over financial reporting were effective as of June 30, 2013; the auditor issued unqualified opinions on the financial statements and internal controls. It also notes prior material weaknesses that management said had been remedied.
Important facts for investors to verify
- Clarify the requested “2012 Q4” period: this filing covers FY2013, and the reported FY2013 fourth quarter had sales of $51.5 million and a net loss of $0.2 million.
- Track recall-related costs, any further quality issues, the effectiveness and cost of added manufacturing controls, and any product-liability exposure.
- Monitor Japanese sales and distributor activity after the market-model transition and product reformulation, including any further regulatory changes.
- Assess whether customer and distributor growth can support sales while operating margins and operating cash flow recover.
- Review the terms and completion of the proposed $40 million tender offer, and potential dilution from outstanding warrants and options exercisable for approximately 15.25 million shares at June 30, 2013.
- Follow the status and potential financial consequences of the distributor lawsuit and any other material proceedings.